Catalent to open new clinical supply facility in Japan
The facility will provide full-service solutions, including project management and clinical supply management, comparator sourcing, secondary packaging and labeling, clinical storage, distribution, and drug return and destruction.
Catalent Pharma Solutions is to introduce clinical supply services at its 200,000 sq. ft. cGMP facility in Kakegawa, Japan. The site, which has been providing oral drug development and manufacturing solutions for more than 40 years, will offer clinical supply solutions to meet the needs of both domestic and global clinical trial sponsors.
The facility will provide full-service solutions, including project management and clinical supply management, comparator sourcing, secondary packaging and labeling, clinical storage, distribution, and drug return and destruction. Construction has already begun at the facility and is expected to be fully validated and operational in the second quarter of 2016. The services it is to provide will complement those from Catalent’s existing footprint in Asia-Pacific, which comprise a full service primary and secondary clinical packaging and storage facility in Shanghai, a secondary packaging and clinical storage facility in Singapore, and an extensive regional depot network.
“Catalent’s site in Kakegawa will play a significant role in serving the market in Japan, the second largest pharmaceutical market worldwide and a key country for new global and domestic clinical trials,” commented Wetteny Joseph, Catalent’s President of Clinical Supply Services. “The Asia-Pacific region is a key part of our strategic growth initiatives and our site in Japan adds to Catalent’s overall clinical supply capabilities in the region, where we will continue to make investments necessary to help meet customers’ existing and future clinical trial demands.”
With facilities in the US, UK, Germany, Singapore, and China, and an extended network of over 50 audited depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, that can help to expedite clinical trials and ensure that customers are reliably supplied where and when needed around the globe.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.